Related references
Note: Only part of the references are listed.A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models
Takeshi Matsumoto et al.
PHARMACEUTICAL RESEARCH (2021)
Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans
Akiko Sarashina et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs
Hua He et al.
PHARMACEUTICS (2019)
Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2,2-difluorodeoxyuridine and their nucleotides
Ellen J. B. Derissen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts
Xu Zhu et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2018)
Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib
Waleed Elsayed Ahmed Ellawatty et al.
DRUG METABOLISM AND DISPOSITION (2018)
Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles
Min Li et al.
AAPS JOURNAL (2017)
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Helen Lee et al.
CLINICAL CANCER RESEARCH (2017)
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Ramesh K. Ramanathan et al.
CLINICAL CANCER RESEARCH (2017)
Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method
T. Yoshikado et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Saturable Hepatic Extraction of Gemcitabine Involves Biphasic Uptake Mediated by Nucleoside Transporters Equilibrative Nucleoside Transporter 1 and 2
Takuya Shimada et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Prediction of Drug Distribution in Subcutaneous Xenografts of Human Tumor Cell Lines and Healthy Tissues in Mouse: Application of the Tissue Composition-Based Model to Antineoplastic Drugs
Patrick Poulin et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
Nicolas Bertrand et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
Ashish V. Kalra et al.
CANCER RESEARCH (2014)
Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition
Leonid Kagan et al.
PHARMACEUTICAL RESEARCH (2014)
The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: A meta-analysis
Hui Li et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2014)
Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro-In Vivo Extrapolation of Clearance of Prodrugs
Haruka Nishimuta et al.
DRUG METABOLISM AND DISPOSITION (2014)
Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption
Yoshihisa Shitara et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2013)
Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions
P. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Malcolm Rowland et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and Bioavailability in mice by 3,4,5,6-tetrahydrouridine
Jan H. Beumer et al.
CLINICAL CANCER RESEARCH (2008)
Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice
Stephan A. Veltkamp et al.
DRUG METABOLISM AND DISPOSITION (2008)
Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics
JA Gilbert et al.
CLINICAL CANCER RESEARCH (2006)
Drug delivery systems: Entering the mainstream
TM Allen et al.
SCIENCE (2004)
Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer
H Achiwa et al.
CANCER SCIENCE (2004)
Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
M Tempero et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
